Get startedLog in
    Picture of Alpine Immune Sciences logo

    ALPN — Alpine Immune Sciences News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapHigh Flyer
    All News

    Brief: Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold On Clinical Trial Of Davoceticept In Combination With Pembrolizumab

    Picture of Alpine Immune Sciences logoAlpine Immune Sciences
    24/05/2022 13:05
    May 24 (Reuters) - Alpine Immune Sciences Inc  ALPN.O :
    * ALPINE IMMUNE SCIENCES ANNOUNCES FDA REMOVES PARTIAL
CLINICAL
HOLD ON NEON-2 CLINICAL TRIAL OF DAVOCETICEPT (ALPN-202) IN
COMBINATION WITH PEMBROLIZUMAB
    * ALPINE IMMUNE SCIENCES INC - FDA REMOVED HOLD AFTER REVIEW
OF
COMPANY'S COMPLETE RESPONSE

Source text for Eikon:  ID:nBw7CK1Y2a 
Further company coverage:  ALPN.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Alpine Immune Sciences

    See all news